In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Xoma nets $9.4mm with private sale of shares

Executive Summary

Xoma (developing antibodies for cancer, inflammation, and autoimmune and infectious diseases) has netted $9.4mm through the sale of units at $0.85 each to an institutional investor. The units consist of one common share (at a 29% premium) and five-year warrants to buy another 5.88mm shares at $1.02 apiece. The company will use the proceeds to continue developing XOMA052, which is in Phase I for Type II diabetes and rheumatoid arthritis, IND studies for gout and systemic juvenile idiopathic arthritis, and preclinical for cardiovascular disease. Canaccord Adams was the placement agent.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies